Recall Record

Princeton, NJ, United States

Sandoz Inc recalls

12 recalls recorded since 2018, most recently on 1 June 2026. 5 are listed as ongoing. Status and classification are as published by the FDA.

Recalls12
Ongoing (FDA)5
Terminated or completed7
Class I (FDA)2

Ongoing Class III Drugs

Recall started
1 June 2026
Reason
Labeling: Incorrect or Missing Lot and/or Exp Date
Distribution
U.S. Nationwide
Initiated
Voluntary: Firm initiated
Recall number
D-0608-2026

Ongoing Class II Drugs

Recall started
5 September 2025
Reason
cGMP deviations: Temperature excursion during transportation.
Distribution
Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall number
D-0651-2025

Ongoing Class II Drugs

Recall started
13 August 2025
Reason
Temperature Abuse
Distribution
Product was distributed to one consignee in CA.
Initiated
Voluntary: Firm initiated
Recall number
D-0626-2025

Ongoing Class I Drugs

Recall started
27 June 2025
Reason
Labeling: Label Mix-Up; cartons of Cefazolin for Injection, USP 1 gram were found to contain vials labeled as penicillin G potassium for Injection, USP, 20 million Unit. The vials contained Cefozalin
Distribution
Nationwide in the USA
Initiated
Voluntary: Firm initiated
Recall numbers
D-0569-2025, D-0570-2025

Terminated Class II Drugs

Recall started
21 March 2022
Terminated
14 August 2023
Reason
CGMP Deviations:Nitrosamine impurity (NMOA) above the acceptable daily limit.
Distribution
Nationwide
Initiated
Voluntary: Firm initiated
Recall number
D-0753-2022

Completed Class I Drugs

Recall started
17 November 2021
Reason
Temperature Abuse; temperature excursion during shipping
Distribution
Nationwide in the US
Initiated
Voluntary: Firm initiated
Recall number
D-0286-2022

Terminated Class II Drugs

Recall started
21 April 2020
Terminated
7 September 2023
Reason
Defective Container: Sub-optimal crimping in vial of Pediatric Infuvite Multiple Vitamins
Distribution
Nationwide within the United States
Initiated
Voluntary: Firm initiated
Recall number
D-1259-2020

Terminated Class III Drugs

Recall started
17 October 2019
Terminated
19 January 2022
Reason
Labeling: Incorrect or missing package insert.
Distribution
Nationwide in the U.S.
Initiated
Voluntary: Firm initiated
Recall numbers
D-0162-2020, D-0163-2020, D-0161-2020

Terminated Class II Drugs

Recall started
23 September 2019
Terminated
14 July 2023
Reason
CGMP Deviations: Detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA).
Distribution
U.S. Nationwide
Initiated
Voluntary: Firm initiated
Recall numbers
D-0127-2020, D-0128-2020, D-0129-2020

Terminated Class II, Class III Drugs

Recall started
2 November 2018
Terminated
2 October 2020
Reason
Cross Contamination with Other Products
Distribution
Nationwide within the United States
Initiated
Voluntary: Firm initiated
Recall numbers
D-0257-2019, D-0262-2019, D-0261-2019, D-0260-2019, D-0258-2019, D-0259-2019

Ongoing Class II Drugs

Recall started
1 November 2018
Reason
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodiethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million.
Distribution
OH, PR
Initiated
Voluntary: Firm initiated
Recall number
D-0359-2019

Terminated Class III Drugs

Recall started
6 April 2018
Terminated
8 April 2019
Reason
Cross Contamination With Other Products: presence of unrelated ingredients (i.e. traces of Lisinopril, Mannitol, Iron, Calcium and Phosphorous).
Distribution
Nationwide in the USA and Puerto Rico
Initiated
Voluntary: Firm initiated
Recall number
D-0631-2018

A terminated FDA recall means the FDA has determined that all reasonable efforts to remove or correct the product have been made. What statuses mean.